Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 9.86B |
| Revenue (ttm) | 4.16B |
| Net Income (ttm) | -368.48M |
| Shares Out | 60.77M |
| EPS (ttm) | -6.06 |
| PE Ratio | n/a |
| Forward PE | 7.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 241,618 |
| Open | 163.75 |
| Previous Close | 163.68 |
| Day's Range | 160.31 - 164.27 |
| 52-Week Range | 95.49 - 182.99 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 207.19 (+27.72%) |
| Earnings Date | Feb 24, 2026 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enry... [Read more]
Financial Performance
In 2024, Jazz Pharmaceuticals's revenue was $4.07 billion, an increase of 6.12% compared to the previous year's $3.83 billion. Earnings were $560.12 million, an increase of 35.02%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price target is $207.19, which is an increase of 27.72% from the latest price.
News
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic cl...
Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript
Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology
Jazz Pharmaceuticals plc is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts. Ziihera's Phase 3 data surpassing Herceptin signals a tra...
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ --...
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard...
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
DUBLIN , Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor W...
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, in...
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher
Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to ...
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
DUBLIN , Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will pa...
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence
Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance ...
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in com...
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom
Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend to...
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing treatment options for patients with rare and aggressive brain tumors For U.S. med...
Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc ( JAZZ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jack Spinks - Executive Director of Investor Relations Renée Galá - President, CEO & Director ...
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelca ® and atezolizumab (Tecentriq ®) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 t...
Aristotle Global Equity Advisory Q3 2025 Contributors And Detractors
MonotaRO, the Japanese business-to-business (B2B) e-commerce platform, was the largest detractor during the quarter. Pawn shop operator FirstCash was the top contributor during the quarter. Aggregates...
Jazz Pharmaceuticals Appoints Ted W. Love, M.D.
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN , Oct. 28, 2025 /PRNewswire/ -- Jazz...
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
DUBLIN , Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the cl...
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it ha...
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street
The S&P 600 Small Cap Index is only up 2.0% year-to-date, but the small-cap trajectory is trending to the upside, with the index returning 5.8% since July.
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab combination added to National Comprehensive Canc...